GeneDx outlines $540M-$555M 2026 revenue target as company accelerates market expansion with new sales force
Source: SeekingAlpha
2026-02-23 12:36:45 ET
More on GeneDx Holdings
- GeneDx Holdings Corp. (WGS) Q4 2025 Earnings Call Transcript
- GeneDx Holdings Corp. (WGS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- GeneDx Holdings Corp. (WGS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- GeneDx Holdings Non-GAAP EPS of $0.18 beats by $0.06, revenue of $121M beats by $0.56M
- GeneDx Holdings Corp. Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
GeneDx outlines $540M–$555M 2026 revenue target as company accelerates market expansion with new sales force
GeneDx Holdings Corp.
NASDAQ: WGS
WGS Trading
4.76% G/L:
$89.40 Last:
72,840 Volume:
$86.75 Open:
WGS Latest News
March 09, 2026 08:30:00 am
GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity(TM) and Real-World Genomic Leadership
February 26, 2026 05:00:14 pm
GeneDx's Chief Operating Officer Sold Nearly 6,000 Shares. Is the Stock a Buy or Sell?
WGS Stock Data
$2,739,577,040
20,348,831
0.11%
111
N/A
Medical Diagnostics & Screening
Healthcare
US
Stamford
